Michigan Clinical Trials Report — May 2026

For Michiganders considering participation in clinical research, May 2026 presents a crucial moment, particularly for those looking to join studies that are nearing their enrollment deadlines. Across the state, 148 clinical trials are slated to close within the next 90 days. This urgency extends to healthy volunteers, with 21 of these rapidly closing studies actively seeking participants without specific health conditions. Individuals interested in contributing to medical advancements should explore these options promptly before they are no longer available.

Groundbreaking Research Arrives in Michigan

This month, Michigan welcomes several high-profile new trials, including significant Phase 3 studies from major pharmaceutical companies. These trials offer participants the chance to engage with cutting-edge treatments addressing prevalent health challenges such as obesity and heart failure.

• Novo Nordisk A/S is sponsoring NCT07567001, a Phase 3 study titled "A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity." This substantial trial aims to evaluate the safety and effect of NNC0487-0111 in individuals with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight. It is designed for a global enrollment of 5,610 participants.
• Another significant Phase 3 study from Novo Nordisk A/S is NCT07564414, "A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight." This trial seeks to enroll 2,500 participants to assess the safety and effectiveness of CagriSema for body weight loss in people with obesity, with or without type 2 diabetes.

Michigan's Evolving Research Landscape

This month, Michigan saw the opening of 4 new clinical trials, a notable decrease compared to the 28 trials that launched in March 2026 and the 26 in April. Despite this dip in new openings, the state continues to offer a broad array of research opportunities, with a total of 2,139 clinical trials currently recruiting across 122 cities and 1,297 research sites.

The new studies this month are exploring a range of conditions, from common ailments to more specialized areas. The conditions targeted by these new trials include:

• Obesity
• Hallux valgus
• Heart failure
• Mental health
• Parenting
• Type 2 diabetes

The types of interventions being studied are varied, with drug trials leading the way, accounting for 2 of the new trials. Additionally, 1 new behavioral trial has opened.

Industry sponsors are driving the majority of new research efforts this month, accounting for 3 of the 4 new studies. Novo Nordisk A/S is a prominent sponsor with 2 new trials, while DePuy Synthes Products, Inc. is sponsoring 1. The University of Michigan is also contributing to the state's research landscape with 1 new trial.

Time is Running Out: Conditions with Impending Deadlines

For patients managing specific health conditions, there are impending deadlines to join research. Trials focused on various types of cancer, neurological disorders, and mental health conditions are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Breast cancer
• Advanced solid tumor
• Prostate cancer
• Cancer (general)
• Triple negative breast cancer
• Major depressive disorder
• Focal epilepsy
• Metastatic cancer
• Cutaneous melanoma
• Advanced breast cancer

These studies represent critical opportunities for patients seeking new treatment options or contributing to the understanding of their conditions before enrollment windows close.

Geographic Reach and Participant Opportunities

The new research initiatives this month are spread across several Michigan cities, indicating a continued effort to make research accessible beyond the largest urban centers. New trials have opened in:

• Ann Arbor
• Bloomfield Hills
• Buckley
• Grand Rapids
• Lansing
• Southfield
• Warren
• Ypsilanti

This distribution allows residents in various parts of the state to find opportunities closer to home. Overall, Michigan's research footprint is extensive, with active trials in 122 cities, ensuring broad accessibility for potential participants.

Participation in clinical trials is open to a wide range of individuals. Of the 4 new trials launched this month, all of them, a total of 4, include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 1 new trial is specifically for female participants. For individuals without a specific medical condition, there are significant opportunities to contribute. 1 of the new trials this month is actively seeking healthy volunteers. Across Michigan, a total of 169 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

As we move through May, the focus will likely shift towards the ongoing enrollment in these significant Phase 3 trials and the 148 studies with rapidly approaching deadlines. Michiganders are encouraged to explore these opportunities, contributing to medical advancements that can benefit their communities and beyond.